Adults and Children:

See full labeling. Individualize. Before receiving treatment: ensure patients have received IGIV at regular intervals for at least 3 months; obtain serum IgG trough level to guide subsequent dose adjustments. Can be administered as a weekly or biweekly SC infusion using an infusion pump into abdomen, thigh, upper arm, or lateral hip areas. For weekly dosing: may use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. Start treatment 1 week after last IGIV infusion. Initial dose: (1.53 x previous IVIG dose [in grams])/number of weeks between IGIV doses; max volume of 15mL/site for first dose; may increase to 20mL/site after the 4th infusion and then to 25mL/site as tolerated; max flow rate of 15mL/hour per site for first dose; may increase to 25mL/hour per site as tolerated for subsequent infusions. For biweekly dosing: increase the number of inj sites as needed. Start treatment 1 or 2 weeks after last IGIV infusion or 1 week after that last weekly Hizentra infusion. Biweekly dose: multiply the calculated weekly dose by 2. Adjust subsequent doses based on desired clinical response and serum IgG trough levels after 2–3 months (see full labeling for dosing chart). Risk of measles exposure: give a minimum weekly dose of 200mg/kg for 2 consecutive weeks; if biweekly dosing: give one infusion at minimum of 400mg/kg. Renal dysfunction or thrombosis risk: give at minimum dose and/or infusion rate practicable.

Contraindications:

IgA-deficiency with antibodies against IgA and history of hypersensitivity. Hyperprolinemia (type I or II). Previous severe reaction to human immune globulin.